Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211145 · ClinicalTrials.gov registry record · Phase 4
Zomig - Treatment of Acute Migraine Headache in Adolescents
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,653
- Enrollment target
NCT01211145 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 1,653 participants.
The verdict
NCT01211145, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,653 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
Interventions
- DRUG Placebo
- DRUG Zolmitriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,653 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211145
The ClinicalTrials.gov registry entry for NCT01211145 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,653 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01211145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01211145 about?
NCT01211145 is a clinical study titled "Zomig - Treatment of Acute Migraine Headache in Adolescents". The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
What is the current status of trial NCT01211145?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,653 participants. The study started on 2010-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01211145?
The interventions under investigation include: Placebo (DRUG), Zolmitriptan (DRUG).
Who is sponsoring clinical trial NCT01211145?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.